

28 July 2026

Biological treatments for Urothelial Cancer

I am currently analysing trends in cancer treatments across the UK. Could you please answer the following question:

How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Atezolizumab (Tecentriq) <5
Avelumab (Bavencio) <5
Carboplatin single agent or in any other combination <5
Carboplatin with Gemcitabine <5
Carboplatin with Gemcitabine + Avelumab (Bavencio) <5
Carboplatin with Paclitaxel <5
Cisplatin single agent or in any other combination <5
Cisplatin with Gemcitabine <5
Cisplatin with Gemcitabine + Nivolumab (Opdivo) <5
Cisplatin with Gemcitabine + Avelumab (Bavencio) <5
Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev) 7
Pembrolizumab (Keytruda) monotherapy <5
Nivolumab (Opdivo) <5
Other active systemic anti-cancer therapy Paclitaxel <5
Palliative care only not available
Erdafitinib <5
Cisplatin + Gemcitabine + Durvalumab (Imfinzi) 6
BCG therapy <5
Chemo-Radiation Therapy no concurrent treatments listed on RISOH

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost

28 July 2026

and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.